Leerink Partnrs Predicts AxoGen FY2029 Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of AxoGen in a report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky forecasts that the medical equipment provider will post earnings per share of $0.38 for the year. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group increased their target price on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday.

AxoGen Stock Up 3.0 %

Shares of NASDAQ AXGN opened at $20.01 on Friday. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $880.60 million, a PE ratio of -62.53 and a beta of 1.00. The stock’s fifty day simple moving average is $17.66 and its two-hundred day simple moving average is $14.99. AxoGen has a 12-month low of $5.55 and a 12-month high of $21.00.

Institutional Trading of AxoGen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of AxoGen by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock valued at $14,170,000 after purchasing an additional 31,612 shares during the last quarter. FMR LLC lifted its holdings in shares of AxoGen by 743.1% during the 3rd quarter. FMR LLC now owns 178,957 shares of the medical equipment provider’s stock valued at $2,509,000 after purchasing an additional 157,730 shares during the last quarter. Barclays PLC lifted its holdings in shares of AxoGen by 119.3% during the 3rd quarter. Barclays PLC now owns 72,036 shares of the medical equipment provider’s stock valued at $1,010,000 after purchasing an additional 39,182 shares during the last quarter. State Street Corp lifted its holdings in shares of AxoGen by 11.9% during the 3rd quarter. State Street Corp now owns 896,674 shares of the medical equipment provider’s stock valued at $12,571,000 after purchasing an additional 95,051 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of AxoGen during the 3rd quarter valued at $207,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.